Project Description:
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) or hematologic malignancy (HM) and to determine whether V212 reduces the incidence of herpes zoster (HZ) in adults with STM or HM, . . .
Key Inclusion and Exclusion Criteria:
Inclusion criteria; •Participant has been diagnosed with an STM or HM and is not likely to undergo hematopoietic cell transplant (HCT) and: •Participant is ≥18 years of age and receiving a cytotoxic or immunosuppressive chemotherapy regimen •Participant is ≥ 50 years of age with a hematolo . . .
Countries of Recruitment:
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Ecuador, Estonia, France, Germany, Greece, Honduras, Hong Kong, Italy, Jordan, Lebanon, Lithuania, Mexico, New Zealand, Panama, Peru, Philippines, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States